沙库巴曲缬沙坦联合磷酸肌酸钠治疗慢性心力衰竭的效果

Efficacy of sacubitril valsartan combined with sodium creatine phosphate in the treatment of chronic heart failure

目的探讨沙库巴曲缬沙坦联合磷酸肌酸钠(PCr)治疗慢性心力衰竭(CHF)的效果。方法抽取2017年4月至2019年12月三门峡市第三人民医院收治的87例CHF患者为研究对象,采用随机数字表法将其分为对照组(44例)与观察组(43例);所有患者均给予常规对症治疗,在此基础上,对照组接受沙库巴曲缬沙坦治疗,观察组在对照组的基础上联合PCr治疗;治疗8周,比较两组治疗效果;比较治疗前、治疗8周时两组心功能、6 min步行实验(6MWT)及血清学相关指标[氨基酸末端B型脑钠肽前体(NT-proBNP)、心型脂肪酸结合蛋白(H-FABP)];记录治疗期间两组不良反应并比较发生率。结果观察组治疗总有效率(95.35%)高于对照组的(81.82%,P<0.05);治疗8周时,观察组左室射血分数(LVEF)、6MWT均高于对照组,左室舒张末期内径(LVEDD)、NT-proBNP、H-FABP水平均低于对照组(P<0.05);两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论 CHF患者在常规治疗基础上采用沙库巴曲缬沙坦联合PCr治疗疗效确切,可提高患者运动耐量,改善其心功能,患者NT-proBNP、H-FABP水平降低,且治疗期间不良反应少,安全有效,临床应用价值高。

Objective To observe the effect of sacubitril valsartan combined with sodium creatine phosphate(PCr)in the treatment of chronic heart failure(CHF).Methods A total of 87 CHF patients who were treated in the Sanmenxia Third Hospital from April 2017 to December 2019 were selected as the research object,and they were divided into control group(44 cases)and observation group(43 cases)by random number table method;All patients were given symptomatic and supportive treatment,on this basis,the control group was treated with sakubatrovalsartan,the observation group was combined with PCr treatment on the basis of the compared control group;they were all treated for 8 weeks,the treatment effect of the two groups were;the cardiac function,6-minute walk test(6MWT)and serological indicators such as amino acid terminal B-type brain natriuretic peptide precursor(NT-proBNP),heart-type fatty acid binding protein(H-FABP)were compared between the two groups before and after 8 weeks of treatment;the incidence of adverse reactions was compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05);8 weeks after treatment,the LVEF and 6MWT of the observation group were higher than the control group,and the levels of LVEDD,NT-proBNP,and H-FABP were lower than that of the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions On the basis of conventional treatment,patients with CHF were treated with salkubatrac valsartan combined with PCr,which can significantly improve patients’cardiac function and exercise tolerance,the levels of NT-proBNP and H-FABP are reduced,and there are few adverse reactions during treatment,which is safe and effective,and the value of clinical application is high.